Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout

뉴스 본문을 불러오고 있어요.

Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout | 웨이프 WAPE

Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout

기사 요약

관련 종목

댓글 —